Showing 8131-8140 of 8693 results for "".
- Almirall, Sun Pharma Enter into a License Agreement for Psoriasis Drug Tildrakizumab in Europehttps://practicaldermatology.com/news/almirall-sun-pharma-enter-into-a-license-agreement-for-psoriasis-drug-tildrakizumab-in-europe/2458485/Sun Pharmaceutical Industries Ltd and Almirall will work together to develop and commercialize tildrakizumab for psoriasis in Europe. Tildrakizumab is an investigational IL-23p19 inhibitor currently being e
- FDA Cracks Down on Mercury in Anti-Aging Productshttps://practicaldermatology.com/news/fda-cracks-down-on-mercury-in-anti-aging-products/2458488/The U.S. Food and Drug Administration is re-issuing a warning about the dangers of mercury in skin creams, beauty and antiseptic soaps, and lotions. In the past few years, the FDA and state health officials
- FDA Advisory Arm Recommends Brodalumab For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-advisory-arm-recommends-brodalumab-for-moderate-to-severe-plaque-psoriasis/2458497/A US. Food and Drug Administration (FDA) advisory panel voted to greenlight Valeant’s IL-17 blocker brodalumab for the treatment of moderate-to-severe plaque psoriasis in adults. The committee voted 18 to 0 in favor of brodalumab injection, 210
- Revance's Injectable Toxin to Enter Phase 3 Trialshttps://practicaldermatology.com/news/revances-injectable-toxin-to-enter-phase-3-trials/2458500/It’s game on for Revance Therapeutics, Inc. The company expects to initiate Phase 3 clinical trials of Injectable DaxibotulinumtoxinA (RT002) for the treatment of glabellar lines in the second half of 2016. Revance is moving forward with an
- ISDIN Launches in the UShttps://practicaldermatology.com/news/isdin-launches-in-the-us/2458501/Barcelona-based ISDIN is officially operating in the US. The company—which operates in Europe, Latin America, and Asia—is bringing its skincare products to the US market. ISDIN’s portfolio of over-the-counter products target
- FDA Advisory Committee Votes to Approve Biosimilar Etanercept from Sandozhttps://practicaldermatology.com/news/fda-advisory-committee-votes-to-approve-biosimilar-etanercept-from-sandoz/2458502/The US FDA Arthritis Advisory Committee recommended approval of Sandoz's proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five indications of the reference product, including rheumatoid arthritis (RA), plaque psoriasis (PsO),
- Valeant Terminates European Licensing Rights for Brodalumabhttps://practicaldermatology.com/news/valeant-terminates-european-licensing-rights-for-brodalumab/2458512/Valeant Pharmaceuticals International, Inc.'s affiliate and AstraZeneca have amended Valeant's license for brodalumab, an IL-17 receptor monoclonal antibody under regulatory review for patients with moderate-to-severe plaque psoriasis, to terminate Valeant's right to develop and comme
- Laser Procedures Seem Generally OK for Psoriasis Patients: Analysishttps://practicaldermatology.com/news/laser-procedures-seem-generally-ok-for-psoriasis-patients-analysis/2458515/Patients with psoriasis who undergo laser procedures do not appear to be at risk for koebnerization, according to research published this spring in Dermatologic Surge
- Analysis Uncovers Health Economic Data for H.P. Acthar® Gel in Dermatomyositis and Polymyositishttps://practicaldermatology.com/news/analysis-uncover-health-economic-data-for-hp-acthar-gel-in-dermatomyositis-and-polymyositis/2458519/Results from two retrospective analyses sponsored by Mallinckrodt plc show that use of the company’s H.P. Acthar® Gel (repository corticotropin injection) offers a cost-effec
- Dr. Ann Marshak-Rothstein Takes Home 2016 Lupus Insight Prize for Cutaneous Lupus Researchhttps://practicaldermatology.com/news/dr-ann-marshak-rothstein-takes-home-2016-lupus-insight-prize-for-cutaneous-lupus-research/2458520/Ann Marshak-Rothstein, PhD, a professor of Medicine/Rheumatology at the University of Massachusetts Medical received the 2016 Lupus Insight Prize for her research on cutaneous lupus. The award was announced at FOCIS 2016, the 16th Annual M